Advertisement

Topics

Transgene S.A. Company Profile

19:54 EDT 21st September 2018 | BioPortfolio

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.


News Articles [42 Associated News Articles listed on BioPortfolio]

Transgene sells Tasly its stake in Transgene Tasly (Tianjin) JV

Transgene SA is selling Tasly Biopharmaceuticals Co. Ltd. its 50% stake of their equally owned Transgene Tasly (Tianjin) BioPharmaceutical Co. virus-based immunotherapies joint venture (formed in 2010...

Tasly, Transgene 50/50 Chinese JV begins operations; later bought out by Tasly Biopharmaceuticals

Tasly Pharmaceutical Group Co. Ltd. and Transgene SA announced that its equally owned joint venture company formed in 2010 has begun operations as Transgene Tasly (Tianjin) Biopharmaceutical Co. in Ti...

Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene

Tasly Biopharma paid $48 million in stock to buy out its China JV partner Transgene (P: TNG), which holds China rights to two Transgene products: T601, an oncolytic virus, and T101, a therapeutic vacc...

Tasly Gains Products As Transgene Sells Up China JV Stake

Transgene is divesting its Chinese joint venture to local partner Tasly, which is also acquiring selected rights to two Transgene...   

Transgene (TNG) - 2018: A year of clinical data

Edison Investment Research - Pharmaceutical & healthcare - Transgene: We anticipate nine of Transgene’s ongoing clinical trials to read out data later this year. This will be the first major tes...

Transgene and Tasly Biopharmaceuticals Conclude Strategic Agreements for the Rights of Transgene's Virus-Based Immunotherapies TG6002 and TG1050 in Greater China

Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares Deals give Tasly Biopharmaceuticals full control over Greater China1 development and commercial rights to the...

Transgene (TNG) - Near-term data to define long-term strategy

Edison Investment Research - Pharmaceutical & healthcare - Transgene: Transgene develops virus-based product candidates for use in oncology and infectious diseases, its five clinical products are curr...

Transgene and Randox to develop innovative multifunctional oncolytic virotherapies for solid tumors

Novel oncolytic virotherapies will be developed by Transgene, based on its next generation Invir.IO Platform and expressing Randox single-domain antibodies (SdAb)

Drugs and Medications [0 Results]

None

PubMed Articles [66 Associated PubMed Articles listed on BioPortfolio]

Synthetic switch-based baculovirus for transgene expression control and selective killing of hepatocellular carcinoma cells.

Baculovirus (BV) holds promise as a vector for anticancer gene delivery to combat the most common liver cancer-hepatocellular carcinoma (HCC). However, in vivo BV administration inevitably results in ...

Effect of transcription terminator usage on the establishment of transgene transcriptional gene silencing.

Obtaining high and stable transgene expression is of vital importance for plant genetic engineering. A lot is known about the relationship between terminator efficiency and gene expression, but no stu...

Application of droplet digital PCR in the analysis of genome integration and organization of the transgene in BAC transgenic mice.

Transgenic (Tg) mice containing bacterial artificial chromosome (BAC) DNA are widely used for gene expression analysis and gene therapy models because BAC transgenes provide gene expression at physiol...

Enhanced transgene expression using cis-acting elements combined with the EF1 promoter in a mammalian expression system.

Transgene expression in eukaryotic cells suffers from epigenetic effects that result in low or unstable transgene expression and high clonal variability. The use of epigenetic regulators is a promisin...

Effects of Different Promoters and Combinations on Transgene Expression of Recombinant CHO Cells.

To analyze the effects of different promoters and matrix attachment region (MAR) on the expression of transgene in Chinese hamster ovary (CHO) cells.

Clinical Trials [9 Associated Clinical Trials listed on BioPortfolio]

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

The primary objective is to evaluate the transgene expression (synthesis of FGF-1 mRNA) in injected tissue, at injection site, after Intra Muscular (IM) administration of increasing single...

A Patient Registry Study for Patients Treated With Voretigene Neparvovec

The objective of this study is to collect long-term safety information (i.e., for 5 years after treatment) associated with voretigene neparvovec-rzyl (vector and/or transgene), its subreti...

Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

Evaluation of Safety, Tolerability, and Efficacy of XT-150, a plasmid DNA with a variant of human IL-10 transgene. XT-150 will be a single injection into the knee synovial capsule for the ...

Performance of the HBV ELISPOT in the Detection of the T Cellular Immune Response in Patients Infected by HBV or Cured

Activation of the immune system against a pathogen can be considered one of the most effective interventions in the field of infectious diseases. Transgene is developing a therapeutic vac...

MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

This is a Phase I-II study evaluating the feasibility, safety, and efficacy of swallowed MnSOD plasmid/liposome (PL) transgene given as protection against radiation-induced esophagitis dur...

Companies [9 Associated Companies listed on BioPortfolio]

Transgene S.A.

Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for th...

Transgene SA

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. It creates, develops and manufactures targeted immunotherapeutics for th...

Transgene

TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited d...

Intrexon Corporation

Intrexon Corporation is a privately held life sciences company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutic...

Transgene Inc

Mission StatementTransgene is a biopharmaceutical company dedicated to the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infec...

More Information about "Transgene S.A." on BioPortfolio

We have published hundreds of Transgene S.A. news stories on BioPortfolio along with dozens of Transgene S.A. Clinical Trials and PubMed Articles about Transgene S.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Transgene S.A. Companies in our database. You can also find out about relevant Transgene S.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record